References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA
Cancer J Clin . 2020; 70:7–30.
- Lima A, Seabra V, Martins S, Coelho A, Araújo A, & Medeiros R.
Thymidylate synthase polymorphisms are associated with the therapeutic
outcome of advanced non-small cell lung cancer patients treated with
platinum-based chemotherapy. Mol. Biol. Rep .2014; 41(5):
3349-3357.
- Choi JR, Kim JO, Kang DR, Shin, JY, Zhang XH, Oh JE, Park JY, Kim KA
and Kang JH. Genetic variations of drug transporters can influence on
drug response in patients treated with docetaxel
chemotherapy. Cancer Res Treat: official journal of Korean
Cancer Association . 2015; 47(3): 509.
- Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA and Sparreboom A.
Modulation of OATP1Btype transporter function alters cellular uptake
and disposition of platinum chemotherapeutics. Mol Cancer Ther.2013; 12(8): 1537-1544.
- Lin L, Yee SW, Kim RB, & Giacomini KM. SLC transporters as
therapeutic targets: emerging opportunities. Nat Rev Drug
discov . 2015: 14 (8): 543-560.
- Sutherland R, Meeson A, Lowes S. Solute transporters and malignancy:
establishing the role of uptake transporters in breast cancer and
breast cancer metastasis. Cancer and Metastasis Reviews .
2020; 39(3):919-932.
- Abdel-Haleem, Alyaa M, et al. Expression of RFC/SLC19A1 is associated
with tumor type in bladder cancer patients. PloS one.2011; 6(7): e21820.
- Chango A, Emery-Fillon N, De Courcy GP et al. A polymorphism
(80G->A) in the reduced folate carrier gene and its
associations with folate status and homocysteinemia. Mol Genet
Metab. 2000;70(4): 310–315.
- Wang L, Chen W, Wang J, Tan Y, Zhou Y, Ding W, et al. Reduced folate
carrier gene G80A polymorphism is associated with an increased risk of
gastroesophageal cancers in a Chinese population. Eur J Cancer .
2006; 42:3206–3211.
- Lima A, Bernardes M, Sousa H, Azevedo R, Costa L, Ventura F, Medeiros
R. SLC19A1 80G allele as a biomarker of methotrexate-related
gastrointestinal toxicity in Portuguese rheumatoid arthritis patients.Pharmacogenomics .2014;15(6): 807-820.
- Adjei AA, Salavaggione OE, MandrekarSJ, DyGK, ZieglerKLA, EndoC,
AdjeiAA. Correlation between polymorphisms of the reduced folate
carrier gene (SLC19A1) and survival after pemetrexed-based therapy in
non-small cell lung cancer: A North Central Cancer Treatment
Group-based exploratory study. J Thorac Oncol . 2010; 5(9):
1346-1353.
- Roth M, Obaidat A, & Hagenbuch B. OATPs, OATs and OCTs: the organic
anion and cation transporters of the SLCO and SLC22A gene
superfamilies. Br J Pharmacol . 2012; 165(5): 1260–1287.
- Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C.
identification of multiple allelic variants associated with altered
transport activity among European and African-Americans. J Biol
Chem . 2001;276(38):35669–75.
- Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y. Functional analysis
of single nucleotide polymorphisms of hepatic organic anion
transporter OATP1B1 (OATP-C). Pharmacogenetics .
2004;14(11):749–57.
- ShitaraY,et al. Clinical significance of organic anion transporting
polypeptides (OATPs) in drug disposition: their roles inhepatic
clearance and intestinal absorption. Biopharm Drug
Dispos .2013;34: 45-78. doi:10.1002/bdd.1823.
- Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Genetic
polymorphisms of human organic anion transporters OATP-C (SLC21A6) and
OATP-B (SLC21A9): allele frequencies in the Japanese population and
functional analysis. J Pharmacol Exp Ther . 2002;302(2):804–13.
- KiyotaniK, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y.
Association of genetic polymorphisms in SLCO1B3 and ABCC2 with
docetaxel‐induced leukopenia. Cancer Sci . 2008; 99(5): 967-972.
- Yamada A, Maeda K, Kiyotani K, Mushiroda T, Nakamura Y, Sugiyama Y.
Kinetic interpretation of the importance of OATP1B3 and MRP2 in
docetaxel‐induced hematopoietic toxicity. CPT: pharmacometrics
& systems pharmacology . 2014; 3(7): 1-10.
- Liu J, Long J, Zhang S, FangX, Luo Y. Polymorphic variants of SLCO1B1
in neonatal hyperbilirubinemia in China. Ital
JPediatr .2013; 39 (1): 1-5.
- Nagy A, Szalai R, Magyari L, Bene J, Toth K,Melegh B. Extreme
differences in SLCO1B3 functional polymorphisms in Roma and Hungarian
populations.EnvironToxicolPharmacol .2015; 39(3): 1246-1251.
- Collin SM, Metcalfe C, Zuccolo L, Lewis SJ, Chen L, Cox A, Davis M,
Lane JA, Donovan J, Smith GD, Neal DE. Association of folate-pathway
gene polymorphisms with the risk of prostate cancer: a
population-based nested case-control study, systematic review, and
meta-analysis. Cancer Epidemiol. Biomark. Prev. 2009
;18(9):2528-2539.
- Liu H, Jin G, Wang H, WuW, Liu Y, Qian J, Sun W. Association of
polymorphisms in one-carbon metabolizing genes and lung cancer risk: a
case-control study in Chinese population. Lung Cancer. 2008;
61(1): 21-29.
- Lima A, BernardesM, AzevedoR, Monteiro J, SousaH, Medeiros R, Seabra
V. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of
methotrexate-related toxicity in Portuguese rheumatoid arthritis
patients. Toxicol Sci. 2014; 142(1):196-209.
- Jabeen S, Holmboe L, Alnæs G IG, Andersen AM, Hall K S, Kristensen VN.
Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma
patients treated with high-dose methotrexate. The
pharmacogenomics journal .2015;15(5): 385-390.
- Lee HH, Ho RH. Interindividual and interethnic variability in drug
disposition: polymorphisms in organic anion transporting polypeptide
1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol. 2017;83:1176-1184.
doi:10.1111/bcp.13207
- Sissung TM et al. Transporter pharmacogenetics: transporter
polymorphisms affect normal physiology, diseases, and pharmacotherapy.Discov Med . 2012;13: 19-34 .
- Liutkeviciene R, Vilkeviciute A, Slavinskaite A, Petrauskaite A,
Tatarunas V, Kriauciuniene L. Evaluation of serum SLCO1B1 levels and
genetic variants of SLCO1B1 rs4149056 and rs2306283 in patients with
early and exudative age-related macular degeneration. Gene .
2018;676:139-45.
- Niemi M, Pasanen MK, Neuvonen P. Organic Anion Transporting
Polypeptide 1B1: A Genetically Polymorphic Transporter of Major
Importance for Hepatic Drug Uptake. Pharmacol.
Rev. 2011;63:157–181. doi: 10.1124/pr.110.002857.
- Gong IY, Kim RB. Impact of Genetic Variation in OATP Transporters to
Drug Disposition and Response. Drug Metab. Pharmacokinet. 2013;
28: 4–18.
- Feng W, Liu X, Zhao X, Huang M, Guo W, Yin J, & Zhu X. Influence of
SLCO1B1 in gastric cancer patients treated with EOF
chemotherapy. Oncol Lett . 2018; 16 (4): 4489-4497.
- Li Y, Gan S, Ren L, Yuan L, Liu J, Wang W, & Qi, X. Multifaceted
regulation and functions of replication factor C family in human
cancers. Am. J. Cancer Res. 2018; 8 (8): 1343.
- Nunez MI, Behrens C, Woods DM, LinH, Suraokar M, Kadara, H, Wistuba,
II. High expression of folate receptor alpha in lung cancer correlates
with adenocarcinoma histology and mutation. J. Thorac. Oncol .
2012; 7 (5): 833-840.
- Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar
M et al . Defective transport is a common mechanism of acquired
methotrexate resistance in acute lymphocytic leukemia and is
associated with decreased reduced folate carrier
expression. Blood .1997; 89: 1013–1018.
- Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri
F, et al. Pharmacogenetic study of patients with advanced non-small
cell lung cancer (NSCLC) treated with second-line pemetrexed or
pemetrexed-carboplatin. Lung Cancer. 2012; 78: 92–9.
- Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, et
al. Randomized phase II and pharmacogenetic study of pemetrexed
compared with pemetrexed plus carboplatin in pretreated patients with
advanced non-small-cell lung cancer. J. Clin. Oncol. 2009; 27:
2038–45.
- Goricar K, Kovac V, & Dolzan V. Polymorphisms in folate pathway and
pemetrexed treatment outcome in patients with malignant pleural
mesothelioma. Radiol oncol . 2014; 48 (2): 163.
- Chew SC, Sandanaraj E, Singh O, Chen X, Tan EH, Lim WT, & Chowbay B.
Influence of SLCO1B3 haplotype‐tag SNPs on docetaxel disposition in
Chinese nasopharyngeal cancer patients. Br. J. Clin. Pharmacol .
2012; 73 (4): 606-618.
- Chew SC, Singh O, Chen X, Ramasamy RD, Kulkarni T, Lee EJD, Tan EH,
Lim WT, Chowbay B. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2
and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics
and pharmacodynamics of docetaxel in nasopharyngeal carcinoma
patients. Cancer Chemother. Pharmacol. 2011;67:1471–8
- Ieiri I, Higuchi S, & Sugiyama Y. Genetic polymorphisms of uptake
(OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for
inter-individual differences in the pharmacokinetics and
pharmacodynamics of statins and other clinically relevant
drugs. Expert Opin Drug Metab Toxicol. 2009; 5 (7):
703-729.
- Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E,
Eskens FA, & Mathijssen RH. Polymorphisms in SLCO1B1 and UGT1A1 are
associated with sorafenib-induced toxicity. Pharmacogenomics .
2016; 17 (14): 1483-1490.
- Robien K, Boynton A, & Ulrich CM. Pharmacogenetics of folate-related
drug targets in cancer treatment. 2005: 673-689.
- Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen R H, & Wiemer
EA. Drug transporters of platinum-based anticancer agents and their
clinical significance. Drug Resist Updat . 2011; 14 (1):
22-34.
- Ho RH, & Kim RB. Transporters and drug therapy: implications for drug
disposition and disease. Clin Pharm Therap . 2005; 78 (3):
260-277.
- Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL and Karlsson
J. Expression of thirty-six drug transporter genes in human intestine,
liver, kidney, and organotypic cell lines. Drug Metab Dispos.2007; 35(8): 1333-1340.
- Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D. &
Relling M V. Germline genetic variation in an organic anion
transporter polypeptide associated with methotrexate pharmacokinetics
and clinical effects. J Clin Oncol . 2009; 27 (35): 5972.
- Plaza-Plaza JC, Aguilera M, Cañadas-Garre M, Chemello C,
González-Utrilla, A, Faus Dader MJ, & Calleja MA. Pharmacogenetic
polymorphisms contributing to toxicity induced by methotrexate in the
southern Spanish population with rheumatoid arthritis. Omics: a
journal of integrative biology . 2012:16 (11); 589-595.
- Owen SA, Hider SL, Martin P, Bruce IN, Barton A, & Thomson W. Genetic
polymorphisms in key methotrexate pathway genes are associated with
response to treatment in rheumatoid arthritis patients. The
pharmacogenomics journal . 2013; 13 (3): 227-234.